title: Response from PHARMAC: difficult choices.
authors.affiliation: PHARMAC, Wellington, New Zealand. peter.moodie@pharmac.govt.nz
authors.forename: Peter
authors.initials: P
authors.lastname: Moodie
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Wayne
authors.initials: W
authors.lastname: McNee
mesh_terms: D005229:Fatty Acids, Monounsaturated / Q000191:economics*; D005252:Fees, Pharmaceutical; D000077340:Fluvastatin; D006077:Government Agencies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D007211:Indoles / Q000191:economics*; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services; D009313:National Health Programs / Q000458:organization & administration*; D009520:New Zealand; D019821:Simvastatin / Q000191:economics*
chemical_list: D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin; D019821:Simvastatin